{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:07:40Z","timestamp":1791248860094,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/bjc.2016.42","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T23:22:20Z","timestamp":1459466540000},"page":"872-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients"],"prefix":"10.1038","volume":"114","author":[{"given":"Angelica","family":"Loskog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aglaia","family":"Maleka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mangsbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margr\u00e9t","family":"Agnarsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Sundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Ahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H","family":"T\u00f6tterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Ullenhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,31]]},"reference":[{"key":"BFbjc201642_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.seminoncol.2012.01.006","volume":"39","author":"C Bernatchez","year":"2012","unstructured":"Bernatchez C, Radvanyi LG, Hwu P (2012) Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol 39: 215\u2013226.","journal-title":"Semin Oncol"},{"key":"BFbjc201642_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","volume":"13","author":"EA Gehan","year":"1961","unstructured":"Gehan EA (1961) The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346\u2013353.","journal-title":"J Chronic Dis"},{"key":"BFbjc201642_CR3","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","volume":"95","author":"TC He","year":"1998","unstructured":"He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509\u20132514.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc201642_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711\u2013723.","journal-title":"N Engl J Med"},{"key":"BFbjc201642_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s13139-013-0255-z","volume":"48","author":"JP Hwang","year":"2014","unstructured":"Hwang JP, Lim I, Na II, Cho EH, Kim BI, Choi CW, Lim SM (2014) Prognostic value of SUVmax measured by fluorine-18 fluorodeoxyglucose positron emission tomography with computed tomography in patients with gallbladder cancer. Nucl Med Mol Imaging 48: 114\u2013120.","journal-title":"Nucl Med Mol Imaging"},{"key":"BFbjc201642_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/187153007780059432","volume":"7","author":"A Loskog","year":"2007","unstructured":"Loskog A, Totterman TH (2007) CD40L - a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets 7: 23\u201328.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"BFbjc201642_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.sder.2010.10.006","volume":"29","author":"J Lutzky","year":"2010","unstructured":"Lutzky J (2010) New therapeutic options in the medical management of advanced melanoma. Semin Cutan Med Surg 29: 249\u2013257.","journal-title":"Semin Cutan Med Surg"},{"key":"BFbjc201642_CR8","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","volume":"16","author":"PU Malmstrom","year":"2010","unstructured":"Malmstrom PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gardmark T, Totterman TH (2010) AdCD40L immunogene therapy for bladder carcinoma\u2013the first phase I\/IIa trial. Clin Cancer Res 16: 3279\u20133287.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201642_CR9","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ncponc0666","volume":"3","author":"P Muranski","year":"2006","unstructured":"Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP (2006) Increased intensity lymphodepletion and adoptive immunotherapy\u2013how far can we go? Nat Clin Pract Oncol 3: 668\u2013681.","journal-title":"Nat Clin Pract Oncol"},{"key":"BFbjc201642_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707\u2013714.","journal-title":"N Engl J Med"},{"key":"BFbjc201642_CR11","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1158\/1078-0432.CCR-13-2151","volume":"19","author":"RJ Sullivan","year":"2013","unstructured":"Sullivan RJ, Lorusso PM, Flaherty KT (2013) The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res 19: 5283\u20135291.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201642_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.cgt.7700527","volume":"10","author":"AW Tong","year":"2003","unstructured":"Tong AW, Stone MJ (2003) Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 10: 1\u201313.","journal-title":"Cancer Gene Ther"},{"key":"BFbjc201642_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","volume":"19","author":"S Ugurel","year":"2001","unstructured":"Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19: 577\u2013583.","journal-title":"J Clin Oncol"},{"key":"BFbjc201642_CR14","first-page":"1953","volume":"149","author":"JJ van den Oord","year":"1996","unstructured":"van den Oord JJ, Maes A, Stas M, Nuyts J, Battocchio S, Kasran A, Garmyn M, De Wever I, De Wolf-Peeters C (1996) CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 149: 1953\u20131961.","journal-title":"Am J Pathol"},{"key":"BFbjc201642_CR15","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","volume":"12","author":"J Weber","year":"2007","unstructured":"Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12: 864\u2013872.","journal-title":"Oncologist"},{"key":"BFbjc201642_CR16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/CJI.0b013e31829d8a1b","volume":"36","author":"S Westberg","year":"2013","unstructured":"Westberg S, Sadeghi A, Svensson E, Segall T, Dimopoulou M, Korsgren O, Hemminki A, Loskog AS, Totterman TH, von Euler H (2013) Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma. J Immunother 36: 350\u2013358.","journal-title":"J Immunother"},{"key":"BFbjc201642_CR17","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35: 1773\u20131782.","journal-title":"Eur J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201642","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:35:56Z","timestamp":1684416956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["BFbjc201642"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.42","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,31]]},"assertion":[{"value":"8 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Loskog is the CEO and board member of Lokon Pharma AB, the chairman of Vivolux AB and RePos Pharma AB, a scientific advisor at NEXTTOBE AB and has a royalty agreement with Alligator Bioscience AB and Lokon Pharma AB. Dr T\u00f6tterman and Dr Mangsbo have a royalty agreement with Alligator Bioscience AB and are board members and shareholders in Immuneed AB. Dr Mangsbo was CEO of Immuneed AB and is employed by AstraZeneca AB. Dr T\u00f6tterman is an advisor of Alligator Bioscience AB. Dr Ullenhag was a Medical Advisor to Lokon Pharma AB. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}